On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading
On 10 March 2021, the World Trade Organization’s (WTO) TRIPS Council addressed the proposal for a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 (IP/C/W/669) under agenda item 12. This proposal is… Continue Reading
Whilst TRIPS Council deliberations in 2020 witnessed some lively deliberations on the nature of legislative amendments to Hungary’ special legal order (State of Danger) to enable the provision of a “compulsory licence regime for public health purposes”, Hungary’s recent decision… Continue Reading
On February 25, 2021, the intellectual property office in Ecuador granted a compulsory license over a patent directed to the raltegravir active ingredient. Raltegravir, commonly marketed under the brand name Isentress, is used to treat HIV infections. The licensed patent… Continue Reading
On 23 February 2021, South Africa delivered two detailed statements at the WTO TRIPS Council’s most recent deliberations on a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 (IP/C/W/669). South Africa did… Continue Reading
New: Biden White House Executive Order opposes change in Bayh-Dole March-In regulations. (KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a… Continue Reading
One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading
On Wednesday 20th January 2020, at the 148th session of the World Health Organisation (WHO) Executive Board, the issue of financing and implementation of programme budget 2020-2021, the draft proposed for programme budget 2022-2023 and the issue of sustainable financing… Continue Reading
On Tuesday, 19 January 2021, the World Health Organization’s (WHO) Executive Board discussed the COVID-19 response. In these discussions, Knowledge Ecology International (KEI), and Health Action International (HAI) expressed concerns over WHO’s leadership of the COVID-19 Technology Access Pool (C-TAP).… Continue Reading
On Monday, 11 January 2021, the secretariat of the World Health Organization (WHO) published an 18 page report on the Global strategy and plan of action on public health, innovation and intellectual property (EB148/10). The Director-General’s report contains a detailed… Continue Reading